Skip to main content

FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics

A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic lateral sclerosis, or ALS.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.